Integrative Research Laboratories Sweden Ab

Nsab, Filial Af Neurosearch Sweden Ab, Sverige

Integrative Research Laboratories

Fredrik Pettersson

Clas Sonesson

Lars Swanson

Nicholas Ross Waters

Susanna Waters

The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R, R, R, Rand Rrepresents H or F, Rrepresents H or CHRrepresents H or C-Calkyl, wherein at least two of R, R, R, Rand Rrepresent F, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

The present disclosure relates to certain novel compounds and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.

Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission

The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.

The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.

3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission

The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives of the invention and to the use of these compounds for therapeutic applications. 

3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.

Growing community of inventors

Göteborg, Sweden

Fredrik Pettersson